Intas becomes the first and only company in India to offer IVF and gynecology therapies with needle-free injections
The collaboration aims to combine synthetic biology with cutting-edge detection technology to create a first-of-its-kind oral pill embedded with tumor-targeting sensors
The drug had previously received orphan drug designation for this rare cancer on March 31, 2025
Masitinib targets mast cells, which play a critical role in severe forms of SCD and its complications, including vaso-occlusive crises, acute chest syndrome, and pain
The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
The portfolio includes foundational patents on the production, composition, and commercial use of NR
Adverse events were consistent with valbenazine’s established safety profile
The study focused on patients without actionable genomic alterations whose disease had progressed after prior immunotherapy and platinum-based chemotherapy
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
Subscribe To Our Newsletter & Stay Updated
